These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17728323)

  • 1. Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti.
    Sebban-Benin H; Pescatore A; Fusco F; Pascuale V; Gautheron J; Yamaoka S; Moncla A; Ursini MV; Courtois G
    Hum Mol Genet; 2007 Dec; 16(23):2805-15. PubMed ID: 17728323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology.
    Gautheron J; Pescatore A; Fusco F; Esposito E; Yamaoka S; Agou F; Ursini MV; Courtois G
    Hum Mol Genet; 2010 Aug; 19(16):3138-49. PubMed ID: 20529958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of interaction between NEMO and SHARPIN impairs linear ubiquitination and NF-κB activation and leads to incontinentia pigmenti.
    Bal E; Laplantine E; Hamel Y; Dubosclard V; Boisson B; Pescatore A; Picard C; Hadj-Rabia S; Royer G; Steffann J; Bonnefont JP; Ursini VM; Vabres P; Munnich A; Casanova JL; Bodemer C; Weil R; Agou F; Smahi A
    J Allergy Clin Immunol; 2017 Dec; 140(6):1671-1682.e2. PubMed ID: 28249776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel inhibitor of nuclear factor kappa-B kinase subunit gamma mutation identified in an incontinentia pigmenti patient with syndromic tooth agenesis.
    Sun S; Li F; Liu Y; Qu H; Wong SW; Zeng L; Yu M; Feng H; Liu H; Han D
    Arch Oral Biol; 2019 May; 101():100-107. PubMed ID: 30913450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation.
    Conze DB; Wu CJ; Thomas JA; Landstrom A; Ashwell JD
    Mol Cell Biol; 2008 May; 28(10):3538-47. PubMed ID: 18347055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.
    Wang Y; Cui L; Yang G; Zhan J; Guo L; Chen Y; Fan C; Liu D; Guo D
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappaB activation.
    Fusco F; Bardaro T; Fimiani G; Mercadante V; Miano MG; Falco G; Israël A; Courtois G; D'Urso M; Ursini MV
    Hum Mol Genet; 2004 Aug; 13(16):1763-73. PubMed ID: 15229184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected].
    Wu CJ; Conze DB; Li T; Srinivasula SM; Ashwell JD
    Nat Cell Biol; 2006 Apr; 8(4):398-406. PubMed ID: 16547522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling.
    Nenci A; Huth M; Funteh A; Schmidt-Supprian M; Bloch W; Metzger D; Chambon P; Rajewsky K; Krieg T; Haase I; Pasparakis M
    Hum Mol Genet; 2006 Feb; 15(4):531-42. PubMed ID: 16399796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease.
    Conte MI; Pescatore A; Paciolla M; Esposito E; Miano MG; Lioi MB; McAleer MA; Giardino G; Pignata C; Irvine AD; Scheuerle AE; Royer G; Hadj-Rabia S; Bodemer C; Bonnefont JP; Munnich A; Smahi A; Steffann J; Fusco F; Ursini MV
    Hum Mutat; 2014 Feb; 35(2):165-77. PubMed ID: 24339369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunodeficiency in Two Female Patients with Incontinentia Pigmenti with Heterozygous NEMO Mutation Diagnosed by LPS Unresponsiveness.
    Ohnishi H; Kishimoto Y; Taguchi T; Kawamoto N; Nakama M; Kawai T; Nakayama M; Ohara O; Orii K; Fukao T
    J Clin Immunol; 2017 Aug; 37(6):529-538. PubMed ID: 28702714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EDA-ID and IP, two faces of the same coin: how the same IKBKG/NEMO mutation affecting the NF-κB pathway can cause immunodeficiency and/or inflammation.
    Fusco F; Pescatore A; Conte MI; Mirabelli P; Paciolla M; Esposito E; Lioi MB; Ursini MV
    Int Rev Immunol; 2015; 34(6):445-59. PubMed ID: 26269396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation.
    Hasegawa M; Fujimoto Y; Lucas PC; Nakano H; Fukase K; Núñez G; Inohara N
    EMBO J; 2008 Jan; 27(2):373-83. PubMed ID: 18079694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase.
    Windheim M; Stafford M; Peggie M; Cohen P
    Mol Cell Biol; 2008 Mar; 28(5):1783-91. PubMed ID: 18180283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEMO, NFkappaB signaling and incontinentia pigmenti.
    Nelson DL
    Curr Opin Genet Dev; 2006 Jun; 16(3):282-8. PubMed ID: 16647846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.
    Zilberman-Rudenko J; Shawver LM; Wessel AW; Luo Y; Pelletier M; Tsai WL; Lee Y; Vonortas S; Cheng L; Ashwell JD; Orange JS; Siegel RM; Hanson EP
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1612-7. PubMed ID: 26802121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel hypomorphic mutation in IKBKG impairs NEMO-ubiquitylation causing ectodermal dysplasia, immunodeficiency, incontinentia pigmenti, and immune thrombocytopenic purpura.
    Ramírez-Alejo N; Alcántara-Montiel JC; Yamazaki-Nakashimada M; Duran-McKinster C; Valenzuela-León P; Rivas-Larrauri F; Cedillo-Barrón L; Hernández-Rivas R; Santos-Argumedo L
    Clin Immunol; 2015 Oct; 160(2):163-71. PubMed ID: 26117626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NESCA: a new NEMO/IKKgamma and TRAF6 interacting protein.
    Napolitano G; Mirra S; Monfregola J; Lavorgna A; Leonardi A; Ursini MV
    J Cell Physiol; 2009 Aug; 220(2):410-7. PubMed ID: 19365808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress.
    Wu ZH; Wong ET; Shi Y; Niu J; Chen Z; Miyamoto S; Tergaonkar V
    Mol Cell; 2010 Oct; 40(1):75-86. PubMed ID: 20932476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAK1 lysine 158 is required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-κB and JNK/AP-1 activation.
    Mao R; Fan Y; Mou Y; Zhang H; Fu S; Yang J
    Cell Signal; 2011 Jan; 23(1):222-7. PubMed ID: 20837137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.